Sugi Predict

Sugi Predict / Compounds / SCHEMBL668469

SCHEMBL668469

SCHEMBL668469

Cc1ccc(C[C@H](N)C(=O)O)c(C)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 3/20 0.50
▸ PKM P14618 2/20 0.50
▸ ALOX15 P16050 2/20 0.50
▸ HIF1A Q16665 2/20 0.50
▸ HSD17B10 Q99714 2/20 0.50
▸ KDM4E B2RXH2 2/20 0.50
▸ RECQL P46063 2/20 0.50
▸ TDP1 Q9NUW8 2/20 0.50
▸ RGS12 O14924 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ NFKB1 P19838 1/20 0.50
▸ CASP1 P29466 1/20 0.50
▸ BRCA1 P38398 1/20 0.50
▸ THPO P40225 1/20 0.50
▸ CASP7 P55210 1/20 0.50
▸ GNAI1 P63096 1/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16098806 1.00 USP2 (0.50) USP2PKMALOX15HIF1AHSD17B10
SCHEMBL668470 1.00 USP2 (0.50) USP2PKMALOX15HIF1AHSD17B10
SCHEMBL29351668 1.00 USP2 (0.50) USP2PKMALOX15HIF1AHSD17B10
Hydrochloric Acid SCHEMBL29175072 0.98 USP2 (0.49) USP2PKMALOX15HIF1AHSD17B10
SCHEMBL15345630 0.86 USP2 (0.50) USP2PKMALOX15HIF1AHSD17B10
SCHEMBL5288482 0.86 USP2 (0.50) USP2PKMALOX15HIF1AHSD17B10
SCHEMBL2028058 0.85 KDM4E (0.62) USP2PKMALOX15HIF1AHSD17B10
SCHEMBL2028640 0.85 KDM4E (0.62) USP2PKMALOX15HIF1AHSD17B10
SCHEMBL2177581 0.85 KDM4E (0.55) USP2PKMALOX15HIF1AHSD17B10
SCHEMBL38096 0.85 KDM4E (0.55) USP2PKMALOX15HIF1AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001922-A1 PEPTIDES TARGETING SODIUM CHANNELS TO TREAT PAIN UNIV CALIFORNIA (US) 2026-01-01 — — US claimed
WO-2024011119-A2 PEPTIDES TARGETING SODIUM CHANNELS TO TREAT PAIN THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-01-11 — — WO claimed
US-20160022636-A1 PHYSIOLOGICAL LIGANDS FOR GPR139 JANSSEN PHARMACEUTICA NV (BE) 2016-01-28 — — US claimed
EP-2968240-A2 PHYSIOLOGICAL LIGANDS FOR GPR139 Janssen Pharmaceutica, N.V. (BE) 2016-01-20 — — EP claimed
US-20140336216-A1 PHYSIOLOGICAL LIGANDS FOR GPR139 JANSSEN PHARMACEUTICA NV (BE) 2014-11-13 — — US claimed
WO-2014152917-A2 PHYSIOLOGICAL LIGANDS FOR GPR139 JANSSEN PHARMACEUTICA NV (BE) 2014-09-25 — — WO claimed
US-20260116921-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES PROTAGONIST THERAPEUTICS INC (US) 2026-04-30 — — US disclosed
US-20260116855-A1 ORALLY ACTIVE MELANOCORTIN RECEPTOR-4 COMPOUNDS PALATIN TECHNOLOGIES INC (US) 2026-04-30 — — US disclosed
EP-3570864-B1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES PROTAGONIST THERAPEUTICS INC (US) 2026-02-18 — — EP disclosed
US-12552836-B2 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases PROTAGONIST THERAPEUTICS, INC. (US) 2026-02-17 — — US disclosed
US-20260001922-A1 PEPTIDES TARGETING SODIUM CHANNELS TO TREAT PAIN UNIV CALIFORNIA (US) 2026-01-01 — — US disclosed
US-12459894-B2 Orally active melanocortin receptor-4 compounds PALATIN TECHNOLOGIES, INC. (US) 2025-11-04 — — US disclosed
EP-4613761-A9 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES Janssen Biotech, Inc. (US) 2025-10-22 — — EP disclosed
EP-0848718-A1 CYTOLYTIC BRADYKININ ANTAGONISTS CORTECH, INC. (US) 1998-06-24 — — EP disclosed
WO-1997046608-A1 TRANSPARENT ANTIBLOCKING FILM BASF AKTIENGESELLSCHAFT (DE) 1997-12-11 — — WO disclosed
EP-0770132-A1 STREPTOGRAMINES AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS Aventis Pharma S.A. (FR) 1997-05-02 — — EP disclosed
WO-1997009347-A1 CYTOLYTIC BRADYKININ ANTAGONISTS CORTECH, INC. (US) 1997-03-13 — — WO disclosed
WO-1997009346-A1 DES-ARG9-BK ANTAGONISTS CORTECH, INC. (US) 1997-03-13 — — WO disclosed
WO-1996016081-A1 BRADYKININ ANTAGONIST PEPTIDES CONTAINING INDANE-SUBSTITUTED AMINO ACIDS UNIVERSITY TECHNOLOGY CORPORATION (US) 1996-05-30 — — WO disclosed
WO-1996001901-A1 STREPTOGRAMINES AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS RHONE-POULENC RORER S.A. (FR) 1996-01-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12459894-B2 Orally active melanocortin receptor-4 compounds MC4R, MC1R, MC3R USP2 4805/4885PKM 2768/4885ALOX15 3157/4885
US-12552836-B2 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases IL23R, IL17A, IL36G USP2 3238/4885PKM 4143/4885ALOX15 1805/4885
US-20260001922-A1 PEPTIDES TARGETING SODIUM CHANNELS TO TREAT PAIN TPX2, XBP1, SCN9A USP2 3598/4885PKM 3978/4885ALOX15 3239/4885
US-20260116921-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES IL23R, IL1RN, IL36G USP2 3861/4885PKM 4749/4885ALOX15 1507/4885
US-20260116855-A1 ORALLY ACTIVE MELANOCORTIN RECEPTOR-4 COMPOUNDS MC1R, MC3R, MC5R USP2 3404/4885PKM 3629/4885ALOX15 1449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.